Changqing Zuo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Changqing Zuo has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Zonggui Wang
Department of Biochemistry and Molecular Biology Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics Guangdong Medical University Dongguan China gdmu.edu.cn
6 shared publicationsZhong Dai
School of Pharmacy Guangdong Medical University Dongguan China gdmu.edu.cn
5 shared publications- Xin-Guang Liu
Department of Hematology, Qilu Hospital of Shandong University, Jinan, China
4 shared publications Liao Cui
Department of Pharmacology, Guangdong Medical University, Dongguan, Guangdong 523808
2 shared publicationsXiuju Chen
Guangdong Provincial Key Laboratory of Research and Development of Natural Drugs, And School of Pharmacy, Guangdong Medical University, Dongguan, 523808, PR China
2 shared publicationsYaqiong Pan
Department of Pharmocology, Guangdong Medical University, Dongguan, Guangdong, 523808, China
2 shared publications
Latest Publications
- 22 February 2022
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 601, 79-85
Transcriptome analysis of long non-coding RNAs reveals NR_015556 lncRNA is a novel regulator for adipocyte differentiation
- 22 February 2022
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 601, 79-85
Transcriptome analysis of long non-coding RNAs reveals NR_015556 lncRNA is a novel regulator for adipocyte differentiation
- Open Access
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
A Novel Long Noncoding RNA, Lnc‐OAD, Is Required for Bone Morphogenetic Protein 2‐ (BMP‐2‐) Induced Osteoblast Differentiation
Long noncoding RNAs (lncRNAs) play very important roles in cell differentiation. Our recent study has demonstrated that a novel lncRNA named lnc‐OAD modulated 3T3‐L1 adipocyte differentiation. In the present study, we examined the roles of lnc‐OAD in bone morphogenetic protein 2‐ (BMP‐2‐) induced osteoblast differentiation. Lnc‐OAD expression was increased during BMP‐2‐induced osteoblast differentiation in C3H10T1/2 mesenchymal stem cells and MC3T3‐E1 preosteoblast cells. Knockdown of lnc‐OAD expression by specific siRNA remarkably decreased early osteoblast differentiation. In addition, stable knockdown of lnc‐OAD by lentivirus vector also significantly inhibited late osteoblast differentiation and matrix mineralization in vitro. Conversely, stably overexpressed lnc‐OAD with lentiviral vector accelerated osteoblast differentiation. Mechanistically, knockdown of lnc‐OAD reduced significantly the phosphorylation of AKT and the expression of Osterix induced by BMP‐2, while overexpression of lnc‐OAD enhanced the phosphorylation of AKT and the expression of Osterix. Taken together, our study suggests that lnc‐OAD plays an important role in modulating BMP‐2‐induced osteoblast differentiation via, at least in part, regulating the AKT‐Osterix signaling axis.
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
Open AccessA Novel Long Noncoding RNA, Lnc‐OAD, Is Required for Bone Morphogenetic Protein 2‐ (BMP‐2‐) Induced Osteoblast Differentiation
Long noncoding RNAs (lncRNAs) play very important roles in cell differentiation. Our recent study has demonstrated that a novel lncRNA named lnc‐OAD modulated 3T3‐L1 adipocyte differentiation. In the present study, we examined the roles of lnc‐OAD in bone morphogenetic protein 2‐ (BMP‐2‐) induced osteoblast differentiation. Lnc‐OAD expression was increased during BMP‐2‐induced osteoblast differentiation in C3H10T1/2 mesenchymal stem cells and MC3T3‐E1 preosteoblast cells. Knockdown of lnc‐OAD expression by specific siRNA remarkably decreased early osteoblast differentiation. In addition, stable knockdown of lnc‐OAD by lentivirus vector also significantly inhibited late osteoblast differentiation and matrix mineralization in vitro. Conversely, stably overexpressed lnc‐OAD with lentiviral vector accelerated osteoblast differentiation. Mechanistically, knockdown of lnc‐OAD reduced significantly the phosphorylation of AKT and the expression of Osterix induced by BMP‐2, while overexpression of lnc‐OAD enhanced the phosphorylation of AKT and the expression of Osterix. Taken together, our study suggests that lnc‐OAD plays an important role in modulating BMP‐2‐induced osteoblast differentiation via, at least in part, regulating the AKT‐Osterix signaling axis.
- 9 November 2020
- Published by Wiley in Phytotherapy Research
- Vol. 35 (4) , 2034-2044
Cycloastragenol protects against glucocorticoid‐induced osteogenic differentiation inhibition by activating telomerase
Glucocorticoid‐induced osteoporosis (GIOP) that is mainly featured as low bone density and increased risk of fracture is prone to occur with the administration of excessive glucocorticoids. Cycloastragenol (CAG) has been verified to be a small molecule that activates telomerase. Studied showed that up‐regulated telomerase was associated with promoting osteogeneic differentiation, so we explored whether CAG could promote osteogenic differentiation to protect against GIOP and telomerase would be the target that CAG exerted its function. Our results demonstrated that CAG prominently increased the ALP activity, mineralization, mRNA of runt‐related transcription factor 2, osteocalcin, osteopontin, collagen type I in both MC3T3‐E1 cells and dexamethasone (DEX)‐treated MC3T3‐E1 cells. CAG up‐regulated telomerase reverse transcriptase and the protective effect of CAG was blocked by telomerase inhibitor TMPyP4. Moreover, CAG improved bone mineralization in DEX‐induced bone damage in a zebrafish larvea model. Therefore, the study showed that CAG could alleviate the osteogenic differentiation inhibition induced by DEX in vitro and in vivo, and CAG might be considered as a candidate drug for the treatment of GIOP.
- 9 November 2020
- Published by Wiley in Phytotherapy Research
- Vol. 35 (4) , 2034-2044
Cycloastragenol protects against glucocorticoid‐induced osteogenic differentiation inhibition by activating telomerase
Glucocorticoid‐induced osteoporosis (GIOP) that is mainly featured as low bone density and increased risk of fracture is prone to occur with the administration of excessive glucocorticoids. Cycloastragenol (CAG) has been verified to be a small molecule that activates telomerase. Studied showed that up‐regulated telomerase was associated with promoting osteogeneic differentiation, so we explored whether CAG could promote osteogenic differentiation to protect against GIOP and telomerase would be the target that CAG exerted its function. Our results demonstrated that CAG prominently increased the ALP activity, mineralization, mRNA of runt‐related transcription factor 2, osteocalcin, osteopontin, collagen type I in both MC3T3‐E1 cells and dexamethasone (DEX)‐treated MC3T3‐E1 cells. CAG up‐regulated telomerase reverse transcriptase and the protective effect of CAG was blocked by telomerase inhibitor TMPyP4. Moreover, CAG improved bone mineralization in DEX‐induced bone damage in a zebrafish larvea model. Therefore, the study showed that CAG could alleviate the osteogenic differentiation inhibition induced by DEX in vitro and in vivo, and CAG might be considered as a candidate drug for the treatment of GIOP.
- Open Access
Identification of Pyrvinium, an Anthelmintic Drug, as a Novel Anti-Adipogenic Compound Based on the Gene Expression Microarray and Connectivity Map
Obesity is a serious health problem, while the current anti-obesity drugs are not very effective. The Connectivity Map (C-Map), an in-silico drug screening approach based on gene expression profiles, has recently been indicated as a promising strategy for drug repositioning. In this study, we performed mRNA expression profile analysis using microarray technology and identified 435 differentially expressed genes (DEG) during adipogenesis in both C3H10T1/2 and 3T3-L1 cells. Then, DEG signature was uploaded into C-Map, and using pattern-matching methods we discovered that pyrvinium, a classical anthelminthic, is a novel anti-adipogenic differentiation agent. Pyrvinium suppressed adipogenic differentiation in a dose-dependent manner, as evidenced by Oil Red O staining and the mRNA levels of adipogenic markers. Furthermore, we identified that the inhibitory effect of pyrvinium was resulted primarily from the early stage of adipogenesis. Molecular studies showed that pyrvinium downregulated the expression of key transcription factors C/EBPa and PPARγ. The mRNA levels of notch target genes Hes1 and Hey1 were obviously reduced after pyrvinium treatment. Taken together, this study identified many differentially expressed genes involved in adipogenesis and demonstrated for the first time that pyrvinium is a novel anti-adipogenic compound for obesity therapy. Meanwhile, we provided a new strategy to explore potential anti-obesity drugs.
Open AccessIdentification of Pyrvinium, an Anthelmintic Drug, as a Novel Anti-Adipogenic Compound Based on the Gene Expression Microarray and Connectivity Map
Obesity is a serious health problem, while the current anti-obesity drugs are not very effective. The Connectivity Map (C-Map), an in-silico drug screening approach based on gene expression profiles, has recently been indicated as a promising strategy for drug repositioning. In this study, we performed mRNA expression profile analysis using microarray technology and identified 435 differentially expressed genes (DEG) during adipogenesis in both C3H10T1/2 and 3T3-L1 cells. Then, DEG signature was uploaded into C-Map, and using pattern-matching methods we discovered that pyrvinium, a classical anthelminthic, is a novel anti-adipogenic differentiation agent. Pyrvinium suppressed adipogenic differentiation in a dose-dependent manner, as evidenced by Oil Red O staining and the mRNA levels of adipogenic markers. Furthermore, we identified that the inhibitory effect of pyrvinium was resulted primarily from the early stage of adipogenesis. Molecular studies showed that pyrvinium downregulated the expression of key transcription factors C/EBPa and PPARγ. The mRNA levels of notch target genes Hes1 and Hey1 were obviously reduced after pyrvinium treatment. Taken together, this study identified many differentially expressed genes involved in adipogenesis and demonstrated for the first time that pyrvinium is a novel anti-adipogenic compound for obesity therapy. Meanwhile, we provided a new strategy to explore potential anti-obesity drugs.
- 1 April 2019
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 511 (4) , 753-758
Long non-coding RNA lnc-OAD is required for adipocyte differentiation in 3T3-L1 preadipocytes
- 1 April 2019
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 511 (4) , 753-758
Long non-coding RNA lnc-OAD is required for adipocyte differentiation in 3T3-L1 preadipocytes
- 15 May 2018
- Published by Wiley in Cell Biology International
- Vol. 42 (7) , 794-803
IL‐1α inhibits proliferation and adipogenic differentiation of human adipose‐derived mesenchymal stem cells through NF‐κB‐ and ERK1/2‐mediated proinflammatory cytokines
Dysfunctional adipogenesis such as subcutaneous lipoatrophy is closely related to insulin resistance and metabolic disorders. Although the expression or release of the cytokine interleukin‐1α (IL‐1α) is known to increase in adipose tissue in response to cell death, cell senescence, aging, or solar radiation, the regulatory role of IL‐1α in adipogenesis has not been sufficiently investigated. To investigate the problem, we explored the effect of IL‐1α on the proliferation and adipogenic differentiation of human adipose‐derived mesenchymal stem cells (ADSCs) using cell counting, alamarBlue assay, oil red O staining, Western blot, among others. The results showed that IL‐1α evidently inhibited the proliferation and adipogenic differentiation of ADSCs, which might be related with the activated nuclear factor‐κB (NF‐κB) and extracellular signal‐regulated kinase (ERK) 1/2 pathways. Early‐stage adipogenic differentiation was more sensitive to IL‐1α than late‐stage differentiation. After differentiation of ADSCs into mature adipocytes, adding of IL‐1α had no obvious influence on the cellular morphology, including lipid droplet accumulation. IL‐1α enhanced the expression of proinflammatory cytokines, such as IL‐8, IL‐6, CCL2 (C‐C motif chemokine ligand 2), and IL‐1β, when added into the adipogenic medium of ADSCs. Blocking IL‐8 and IL‐6 with neutralizing antibodies partially alleviated the inhibitory effect of IL‐1α on the proliferation and adipogenic differentiation. The results suggest that IL‐1α inhibits adipogenesis through activation of NF‐κB and ERK1/2 pathways and subsequent upregulation of proinflammatory cytokines in ADSCs. IL‐1α might play an important role in mediating lipoatrophy by regulation of ADSCs.
- 15 May 2018
- Published by Wiley in Cell Biology International
- Vol. 42 (7) , 794-803
IL‐1α inhibits proliferation and adipogenic differentiation of human adipose‐derived mesenchymal stem cells through NF‐κB‐ and ERK1/2‐mediated proinflammatory cytokines
Dysfunctional adipogenesis such as subcutaneous lipoatrophy is closely related to insulin resistance and metabolic disorders. Although the expression or release of the cytokine interleukin‐1α (IL‐1α) is known to increase in adipose tissue in response to cell death, cell senescence, aging, or solar radiation, the regulatory role of IL‐1α in adipogenesis has not been sufficiently investigated. To investigate the problem, we explored the effect of IL‐1α on the proliferation and adipogenic differentiation of human adipose‐derived mesenchymal stem cells (ADSCs) using cell counting, alamarBlue assay, oil red O staining, Western blot, among others. The results showed that IL‐1α evidently inhibited the proliferation and adipogenic differentiation of ADSCs, which might be related with the activated nuclear factor‐κB (NF‐κB) and extracellular signal‐regulated kinase (ERK) 1/2 pathways. Early‐stage adipogenic differentiation was more sensitive to IL‐1α than late‐stage differentiation. After differentiation of ADSCs into mature adipocytes, adding of IL‐1α had no obvious influence on the cellular morphology, including lipid droplet accumulation. IL‐1α enhanced the expression of proinflammatory cytokines, such as IL‐8, IL‐6, CCL2 (C‐C motif chemokine ligand 2), and IL‐1β, when added into the adipogenic medium of ADSCs. Blocking IL‐8 and IL‐6 with neutralizing antibodies partially alleviated the inhibitory effect of IL‐1α on the proliferation and adipogenic differentiation. The results suggest that IL‐1α inhibits adipogenesis through activation of NF‐κB and ERK1/2 pathways and subsequent upregulation of proinflammatory cytokines in ADSCs. IL‐1α might play an important role in mediating lipoatrophy by regulation of ADSCs.
- 1 October 2017
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 492 (3) , 419-424
E3 ubiquitin ligase DTX4 is required for adipogenic differentiation in 3T3-L1 preadipocytes cell line
- 1 October 2017
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 492 (3) , 419-424
E3 ubiquitin ligase DTX4 is required for adipogenic differentiation in 3T3-L1 preadipocytes cell line
- Open Access
- 15 September 2016
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 38 (5) , 1411-1418
Lrrc75b is a novel negative regulator of C2C12 myogenic differentiation
Many transcription factors and signaling molecules involved in the guidance of myogenic differentiation have been investigated in previous studies. However, the precise molecular mechanisms of myogenic differentiation remain largely unknown. In the present study, by performing a meta-analysis of C2C12 myogenic differentiation microarray data, we found that leucine-rich repeat-containing 75B (Lrrc75b), also known as AI646023, a molecule of unknown biological function, was downregulated during C2C12 myogenic differentiation. The knockdown of Lrrc75b using specific siRNA in C2C12 myoblasts markedly enhanced the expression of muscle-specific myogenin and increased myoblast fusion and the myotube diameter. By contrast, the adenovirus-mediated overexpression of Lrrc75b in C2C12 cells markedly inhibited myoblast differentiation accompanied by a decrease in myogenin expression. In addition, the phosphorylation of extracellular signal-regulated kinase 1/2 (Erk1/2) was suppressed in the cells in which Lrrc75b was silenced. Taken together, our results demonstrate that Lrrc75b is a novel suppressor of C2C12 myogenic differentiation by modulating myogenin and Erk1/2 signaling.
- 15 September 2016
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 38 (5) , 1411-1418
Open AccessLrrc75b is a novel negative regulator of C2C12 myogenic differentiation
Many transcription factors and signaling molecules involved in the guidance of myogenic differentiation have been investigated in previous studies. However, the precise molecular mechanisms of myogenic differentiation remain largely unknown. In the present study, by performing a meta-analysis of C2C12 myogenic differentiation microarray data, we found that leucine-rich repeat-containing 75B (Lrrc75b), also known as AI646023, a molecule of unknown biological function, was downregulated during C2C12 myogenic differentiation. The knockdown of Lrrc75b using specific siRNA in C2C12 myoblasts markedly enhanced the expression of muscle-specific myogenin and increased myoblast fusion and the myotube diameter. By contrast, the adenovirus-mediated overexpression of Lrrc75b in C2C12 cells markedly inhibited myoblast differentiation accompanied by a decrease in myogenin expression. In addition, the phosphorylation of extracellular signal-regulated kinase 1/2 (Erk1/2) was suppressed in the cells in which Lrrc75b was silenced. Taken together, our results demonstrate that Lrrc75b is a novel suppressor of C2C12 myogenic differentiation by modulating myogenin and Erk1/2 signaling.
- Open Access
- 21 June 2013
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 8 (2) , 463-467
Expression profiling of lncRNAs in C3H10T1/2 mesenchymal stem cells undergoing early osteoblast differentiation
Protein‑coding genes and small non‑coding microRNAs involved in the guidance of differentiation in mesenchymal stem cells (MSCs) into osteoblasts have been extensively investigated in previous studies. However, long non‑coding RNAs (lncRNAs), which account for a large proportion of the genomic sequences in numerous species, have not yet been reported. In the present study, the lncRNA expression profile was analyzed using the Arraystar lncRNA array in C3H10T1/2 MSCs undergoing early osteoblast differentiation and 116 differentially expressed lncRNAs were identified between BMP‑2 treated and untreated groups. Among these lncRNAs, 59 were upregulated and 57 were downregulated in BMP‑2 treated groups. In addition, 24 cooperatively differentially expressed lncRNAs and nearby mRNA pairs were found. For example, mouselincRNA0231 and its nearby gene, EGFR, were downregulated, while lncRNA NR_027652 and its nearby gene, DLK1, were upregulated. These observations may be part of the regulatory mechanisms of lncRNAs in the control of osteoblast differentiaton. In conclusion, results of the present study indicate that lncRNA expression profiles are significantly altered in C3H10T1/2 undergoing early osteoblast differentiation and these results may provide insight into the mechanisms responsible for osteoblast differentiation.
- 21 June 2013
- Published by Spandidos Publications in Molecular Medicine Reports
- Vol. 8 (2) , 463-467
Open AccessExpression profiling of lncRNAs in C3H10T1/2 mesenchymal stem cells undergoing early osteoblast differentiation
Protein‑coding genes and small non‑coding microRNAs involved in the guidance of differentiation in mesenchymal stem cells (MSCs) into osteoblasts have been extensively investigated in previous studies. However, long non‑coding RNAs (lncRNAs), which account for a large proportion of the genomic sequences in numerous species, have not yet been reported. In the present study, the lncRNA expression profile was analyzed using the Arraystar lncRNA array in C3H10T1/2 MSCs undergoing early osteoblast differentiation and 116 differentially expressed lncRNAs were identified between BMP‑2 treated and untreated groups. Among these lncRNAs, 59 were upregulated and 57 were downregulated in BMP‑2 treated groups. In addition, 24 cooperatively differentially expressed lncRNAs and nearby mRNA pairs were found. For example, mouselincRNA0231 and its nearby gene, EGFR, were downregulated, while lncRNA NR_027652 and its nearby gene, DLK1, were upregulated. These observations may be part of the regulatory mechanisms of lncRNAs in the control of osteoblast differentiaton. In conclusion, results of the present study indicate that lncRNA expression profiles are significantly altered in C3H10T1/2 undergoing early osteoblast differentiation and these results may provide insight into the mechanisms responsible for osteoblast differentiation.
- Open Access
- 5 May 2009
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 23 (6) , 811-819
Enriching protein-protein and functional interaction networks in human embryonic stem cells
Human Embryonic Stem Cells (hESCs) have a great therapeutic potential in regenerative medicine, but the precise molecular mechanisms by which hESCs maintain or regulate their characteristics remain largely unknown. Since protein-protein interaction is vitally important in regulating hESCs, we utilized a network-based bioinformatics analysis in order to learn what and how specific proteins interact with each other. By combining protein-protein interaction data and a collection of genes over-expressed in hESCs, we constructed a protein interaction network using a breadth-first search algorithm. This scale-free network which is significantly larger than networks generated by random samplings, illustrates how these hESC-enriched proteins might interact with each other in hESCs. Of the top 5% highly connected nodes (corresponding to 21 proteins including MYC, H2AFX, RUVBL1, DDX18, CDC2, HDAC2 and HIST1H4C) presumably critical for determining the fate of hESCs, nearly half are known to be regulated by NANOG/SOX2/MYC. This underscores importance of these transcription factors in hESCs. In addition, in silico cis-element analysis suggests that NF-Y may be an important transcription factor regulating many of these hub proteins (high connected nodes) in hESCs. To further abstract the functional significance, directly connected proteins were matched to and grouped by gene ontology (GO) terms in molecular function category. Sixty- six interacting GO-GO terms paired through protein interactions were found over-represented in hESCs. This functional enrichment may be essential for understanding molecular characteristics in hESCs. Collectively, we analyzed hESC-enriched genes based on protein-protein interaction data, from which an hESC-enriched protein interaction network was constructed and a network of molecular functional terms was also identified. The results of this analysis, on the systems level, may shed new light to further our understanding of hESCs.
- 5 May 2009
- Published by Spandidos Publications in International Journal of Molecular Medicine
- Vol. 23 (6) , 811-819
Open AccessEnriching protein-protein and functional interaction networks in human embryonic stem cells
Human Embryonic Stem Cells (hESCs) have a great therapeutic potential in regenerative medicine, but the precise molecular mechanisms by which hESCs maintain or regulate their characteristics remain largely unknown. Since protein-protein interaction is vitally important in regulating hESCs, we utilized a network-based bioinformatics analysis in order to learn what and how specific proteins interact with each other. By combining protein-protein interaction data and a collection of genes over-expressed in hESCs, we constructed a protein interaction network using a breadth-first search algorithm. This scale-free network which is significantly larger than networks generated by random samplings, illustrates how these hESC-enriched proteins might interact with each other in hESCs. Of the top 5% highly connected nodes (corresponding to 21 proteins including MYC, H2AFX, RUVBL1, DDX18, CDC2, HDAC2 and HIST1H4C) presumably critical for determining the fate of hESCs, nearly half are known to be regulated by NANOG/SOX2/MYC. This underscores importance of these transcription factors in hESCs. In addition, in silico cis-element analysis suggests that NF-Y may be an important transcription factor regulating many of these hub proteins (high connected nodes) in hESCs. To further abstract the functional significance, directly connected proteins were matched to and grouped by gene ontology (GO) terms in molecular function category. Sixty- six interacting GO-GO terms paired through protein interactions were found over-represented in hESCs. This functional enrichment may be essential for understanding molecular characteristics in hESCs. Collectively, we analyzed hESC-enriched genes based on protein-protein interaction data, from which an hESC-enriched protein interaction network was constructed and a network of molecular functional terms was also identified. The results of this analysis, on the systems level, may shed new light to further our understanding of hESCs.